Physician profile
Jon Slotoroff
NPI 1760565071
$3,674.83
in general payments reported to CMS, 2019-2025
27 companies · $563 in 2025
The $563 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,038 · 2020: $843 · 2021: $569 · 2022: $25.37 · 2023: $138 · 2024: $499 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,199.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $909.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $676.19 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $517.96 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $182.47 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.72 | 2019-2025 | Jardiance |
| Allergan, INC. | $156.91 | 2019 | |
| Sanofi-Aventis U.S. LLC | $108.18 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $96.48 | 2020-2025 | Zoryve |
| Merck Sharp & Dohme LLC | $93.25 | 2019-2021 | |
| Astellas Pharma US INC | $85.28 | 2019-2025 | Veozah |
| Medtronic, INC. | $81.55 | 2023 | Corevalve Evolut R |
| Arbor Pharmaceuticals, INC. | $79.40 | 2019-2020 | |
| Abbvie INC. | $70.48 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.86 | 2020-2025 | Xifaxan |
| Amarin Pharma, INC. | $58.66 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $51.02 | 2019-2021 | |
| Amgen INC. | $49.10 | 2024-2025 | Repatha |
| Abbott Laboratories | $41.96 | 2021-2023 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $27.96 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $26.77 | 2021 | |
| Sanofi Pasteur INC. | $25.59 | 2019 | |
| Eisai INC. | $25.51 | 2021 | |
| Exact Sciences Corporation | $24.79 | 2024 | Cologuard Collection Kit |
| Lundbeck LLC | $19.38 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $18.51 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $13.73 | 2019 | |
| Pfizer INC. | $12.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Slotoroff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.